Peginesatide - an overview | ScienceDirect Topics
Peginesatide is a peptide drug designed to mimic the biological activity of Epo. It binds to the human Epo-R and activates the receptor to stimulate erythropoiesis in human red cell precursors [38]. In 2012, the FDA approved it to treat patients with renal failure–induced anemia.
Peginesatide - an overview | ScienceDirect Topics
Peginesatide is a PEGylated synthetic peptide which mimics the structure of erythropoietin and promotes red cell development. Peginesatide was non-inferior to standard ESAs in increasing and maintaining target hemoglobin levels.
Peginesatide - an overview | ScienceDirect Topics
Peginesatide (earlier named Hematide™), a pegylated homodimer of two EMPs, was approved as an antianemic medicine for the treatment of patients with CKD in the USA in 2012 but recalled in 2013 due to prevalent cases of acute anaphylactoid reactions.
Peginesatide - Wikipedia
Peginesatide [2] (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis .
Lessons learned from peginesatide in the treatment of anemia …
2013年11月11日 · Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients.
Peginesatide and Erythropoietin Stimulate Similar Erythropoietin ...
Peginesatide has been shown to stimulate sustained erythropoiesis in vivo allowing for once monthly dosing, and has recently been approved for the treatment of anemia associated with chronic kidney disease in patients on dialysis [6–9].
Peginesatide: Uses, Interactions, Mechanism of Action - DrugBank …
Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself.
Profile of peginesatide and its potential for the treatment of …
Peginesatide is a synthetic, dimeric peptide that is covalently linked to polyethylene glycol (PEG). The amino acid sequence of peginesatide is unrelated to that of erythropoietin (EPO) and is not immunologically cross-reactive with EPO. Peginesatide binds to …
Peginesatide to Manage Anemia in Chronic Kidney Disease …
2012年9月4日 · Peginesatide is a novel, synthetic, peptide-based pegylated erythropoiesis-stimulating agent that is designed specifically to stimulate the erythropoietin receptor. The purpose of the present study was to assess, for the first time, the efficacy and safety of peginesatide in chronic kidney disease (CKD) patients receiving peritoneal dialysis ...
Peginesatide for the treatment of renal disease-induced anemia
2013年4月8日 · Expert opinion: Peginesatide has a well-studied pharmacological and immunological profile, and latest published data favor the use of peginesatide in place of epoetin in dialysis patients. A more detailed evaluation of its safety profile particularly in trials with CKD patients not requiring dialysis is urgently needed, as peginesatide could be ...